

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP

RRID:AB_2535600

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# A18823, RRID:AB_2535600

Antibody Information

URL: http://antibodyregistry.org/AB_2535600

Proper Citation: Thermo Fisher Scientific Cat# A18823, RRID:AB_2535600

Target Antigen: Human IgG Fc

Host Organism: goat

Clonality: polyclonal secondary

Comments: Applications: WB (1:500-1:20,000), ELISA (1:500-1:20,000), IHC (1:500-1:20,000)

Antibody Name: Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP

Description: This polyclonal secondary targets Human IgG Fc

Target Organism: human

Antibody ID: AB_2535600

Vendor: Thermo Fisher Scientific

Catalog Number: A18823

Record Creation Time: 20231110T035511+0000

Record Last Update: 20260831T221334+0000

Ratings and Alerts

No rating or validation information has been found for Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP.

No alerts have been found for Goat anti-Human IgG Fc Cross-Adsorbed Secondary Antibody, HRP.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Durham ND, et al. (2025) Molecular basis for the increased fusion activity of the Ebola virus glycoprotein epidemic variant A82V: Insights from simulations and experiments. Cell reports, 44(4), 115521.

Ullah I, et al. (2023) The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell reports. Medicine, 4(1), 100893.

Ferhat M, et al. (2023) The newly engineered monoclonal antibody ON104, targeting the oxidized Macrophage Migration Inhibitory Factor (oxMIF), ameliorates clinical and histopathological signs of collagen-induced arthritis. European journal of pharmacology, 956, 175997.

Chen Y, et al. (2023) Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. iScience, 26(1), 105783.

Rossmueller G, et al. (2023) Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. Molecular cancer therapeutics, 22(5), 555.

Richard J, et al. (2023) Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120. Cell chemical biology, 30(5), 540.

Li W, et al. (2022) Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell reports, 38(2), 110210.

Venkataraman T, et al. (2022) Comprehensive profiling of antibody responses to the human anellome using programmable phage display. Cell reports, 41(12), 111754.

Beaudoin-Bussi res G, et al. (2022) A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell reports, 38(7), 110368.

Prévost J, et al. (2022) HIV-1 Vpu restricts Fc-mediated effector functions in vivo. *Cell reports*, 41(6), 111624.

Ullah I, et al. (2021) Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. *Immunity*, 54(9), 2143.

Anand SP, et al. (2021) Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. *Cell reports. Medicine*, 2(6), 100290.

Rajashekar JK, et al. (2021) Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. *Cell host & microbe*, 29(6), 904.

Lu M, et al. (2020) Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. *Cell host & microbe*, 28(6), 880.

Prévost J, et al. (2020) Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. *Cell reports. Medicine*, 1(7), 100126.